FavorableClasse Défavorable floue DT50 (jour) 1 30 GUS 1,8 2,8 Constante Henry KH 2,65 E-6 2,65E-4 DJA (mg.kg -1.day -1 ) 1 0,0001 Aquatox (mg.l -1 )
A phase III study of gemcitabine ± docetaxel for metastatic soft tissue sarcoma Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno S, Samuels B, Harmon DC,
1 Rationale for the effective use of pharmacokinetics and pharmacodynamics in drug development P.L. Toutain ECOLE NATIONALE VETERINAIRE T O U L O U S E.
A phase III study of gemcitabine ± docetaxel for metastatic soft tissue sarcoma
